Nitric Oxide–Induced Motility in Aortic Smooth Muscle Cells
- 6 September 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 91 (5) , 390-397
- https://doi.org/10.1161/01.res.0000033524.92083.64
Abstract
We have previously reported that SHP-2 upregulation is necessary for NO-stimulated motility in differentiated rat aortic smooth muscle cells. We now test the hypothesis that upregulation of SHP-2 is necessary and sufficient to stimulate cell motility. Overexpression of SHP-2 via recombinant adenoviral vector stimulated motility to the same extent as NO, whereas the expression of C463S-SHP-2, the dominant-negative SHP-2 allele, blocked the motogenic effect of NO. On the basis of previous studies, we next tested the hypothesis that NO decreases RhoA activity and that this event is necessary and sufficient to explain NO-induced motogenesis. We found that NO decreased RhoA activity in a concentration-dependent manner. Moreover, a dominant-negative SHP-2 allele, DSH2, blocked the NO-induced inhibition of RhoA activity, indicating that upregulation of SHP-2 is necessary for this event. Expression of G14V-RhoA, the constitutively active RhoA allele, decreased cell motility and blocked the motogenic effect of NO, whereas the expression of T19N-RhoA, the dominant-negative RhoA allele, increased cell motility to an extent similar to that induced by NO. Dominant-negative RhoA reversed the effect of dominant-negative SHP-2, indicating that RhoA functions downstream from SHP-2. To investigate events downstream from RhoA, we treated cells with fasudil, a selective Rho kinase inhibitor, and found that it increased cell motility. These results indicate that upregulation of SHP-2, leading to downregulation of RhoA, which is followed by decreased Rho kinase activity, is a sequence of events necessary and sufficient to explain NO-induced cell motility in differentiated aortic smooth muscle cells. The results may be of relevance to in vivo events such as neointimal formation, angiogenesis, and vasculogenesis.Keywords
This publication has 40 references indexed in Scilit:
- Site-Specific Incorporation of a Phosphotyrosine Mimetic Reveals a Role for Tyrosine Phosphorylation of SHP-2 in Cell SignalingMolecular Cell, 2001
- cGMP-Dependent Protein Kinase Phosphorylates and Inactivates RhoABiochemical and Biophysical Research Communications, 2001
- Cyclic GMP-dependent Protein Kinase Signaling Pathway Inhibits RhoA-induced Ca2+ Sensitization of Contraction in Vascular Smooth MuscleJournal of Biological Chemistry, 2000
- The Kinase Inhibitor Fasudil (HA-1077) Reduces Intimal Hyperplasia through Inhibiting Migration and Enhancing Cell Loss of Vascular Smooth Muscle CellsBiochemical and Biophysical Research Communications, 1999
- SHP-2 binds to Tyr763 and Tyr1009 in the PDGF β-receptor and mediates PDGF-induced activation of the Ras/MAP kinase pathway and chemotaxisOncogene, 1999
- Exogenous nitric oxide inhibits mesangial cell adhesion to extracellular matrix componentsKidney International, 1998
- Effects of nitric oxide on the adhesion of human melanocytes to extracellular matrix componentsThe Journal of Pathology, 1997
- Predominant expression of the src homology 2-containing tyrosine phosphatase protein SHP2 in vascular smooth muscle cellsVirchows Archiv, 1997
- Protein-tyrosine Phosphatase 1D Modulates Its Own State of Tyrosine PhosphorylationJournal of Biological Chemistry, 1995
- DIFFERENTIAL REGULATION BY TRANSFORMING GROWTH FACTOR‐β1 OF PLATELET‐DERIVED GROWTH FACTOR‐ STIMULATED PROLIFERATION OF VASCULAR SMOOTH MUSCLE CELLS FROM SHR AND WKY RATSClinical and Experimental Pharmacology and Physiology, 1992